Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated FOLFOX ± Cetuximab

Researchers examined the prognostic value of BRAF and KRAS mutations in patients with stage III colon cancer who received FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with or without cetuximab.

BRAF V600E and KRAS mutations were significantly associated with shorter disease-free and overall survival in patients with microsatellite-stable tumors but not in patients with microsatellite instability phenotype.

http://oncology.jamanetwork.com/article.aspx?articleid=2481020#tab12